A study to assess the effect of erythromycin on the test medicine (SAR443820) when given orally as tablets to healthy adult male and female participants (Part A); and the effect of itraconazole on the test medicine (SAR443820) when given orally as capsules to healthy adult male participants (Part B) [This study has been transferred to Denali Therapeutics Inc.; ClinicalTrials.gov ID: NCT05797753]

Trial Identifier: INT17470
Sponsor: Sanofi
Start Date: February 2022
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Healthy Volunteers; Amyotrophic lateral sclerosis (ALS)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
This study has been transferred to Denali Therapeutics Inc. For any questions, please contact [email protected]

Trial Locations

Country Location
UNITED STATES, Minnesota St. Paul, Minnesota, UNITED STATES, 55114